2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

Samir Mitragotri

Workshop 1  –  Technology & Entrepreneurship
Date: 24 July (Friday) 10:40 – 12:10 (GMT+8)
Venue: www.bioasiataiwan.com - Online event platform


​​

Samir Mitragotri

Professor
Harvard University


 

Samir Mitragotri is the Hiller Professor of Bioengineering and Wyss Professor of Biologically Inspired Engineering at Harvard University. His research has provided new insights to address challenges associated with drug development, especially by developing new methods for drug delivery. He is an author of over 300 publications and is a Highly Cited Researcher. Prof Mitragotri is an inventor on over 180 patent/patent applications. His inventions have led to several products that have been commercialized or are in advanced clinical development.  Prof. Mitragotri is recognized by numerous awards. He is an elected member of the US National Academy of Engineering, US National Academy of Medicine and US National Academy of Inventors. He is also a foreign member of Indian National Academy of Engineering. Prof. Mitragotri is also an elected fellow of American Association of Advancement of Science, Controlled Release Society, Biomedical Engineering Society, American Institute of Medical and Biological Engineering, and American Association of Pharmaceutical Scientists. He received BS in Chemical Engineering from the Institute of Chemical Technology, India and PhD in Chemical Engineering from the Massachusetts Institute of Technology. He is the Editor-in-Chief of Bioengineering and Translational Medicine


Speech title & Synopsis

Ionic Liquids as a Technology Platform for Biologics Delivery

Oral delivery is a simple and patient-compliant means of administering drugs. However, this route is not available to biologics which constitute a large fraction of today’s drug landscape. Oral absorption of biologics is limited by their enzymatic degradation and poor permeation across the intestinal epithelium. Our laboratory has developed ionic liquids for overcoming these barriers. I will describe the principles of ionic-liquid based oral biologics delivery and path to the commercial translation of this platform.